dacarbazine and Encephalopathy, Toxic

dacarbazine has been researched along with Encephalopathy, Toxic in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Muldoon, LL; Netto, JP; Neuwelt, EA; Pagel, MA	1
Schiff, D; van den Bent, MJ; Wen, PY	1
Cheung, MC; Hicks, LK; Leitch, HA	1

Reviews

1 review(s) available for dacarbazine and Encephalopathy, Toxic

Article	Year
Neurological adverse effects caused by cytotoxic and targeted therapies. Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:10 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bevacizumab; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dacarbazine; Drug Approval; Epothilones; Humans; Imatinib Mesylate; Indoles; Neoplasms; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Piperazines; Pyrazines; Pyrimidines; Pyrroles; Sunitinib; Temozolomide; Tubulin Modulators; United States; United States Food and Drug Administration	2009

Article

Year

Neurological adverse effects caused by cytotoxic and targeted therapies.

Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:10

Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bevacizumab; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dacarbazine; Drug Approval; Epothilones; Humans; Imatinib Mesylate; Indoles; Neoplasms; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Piperazines; Pyrazines; Pyrimidines; Pyrroles; Sunitinib; Temozolomide; Tubulin Modulators; United States; United States Food and Drug Administration

2009

Other Studies

2 other study(ies) available for dacarbazine and Encephalopathy, Toxic

Article	Year
Intra-arterial administration improves temozolomide delivery and efficacy in a model of intracerebral metastasis, but has unexpected brain toxicity. Journal of neuro-oncology, 2016, Volume: 126, Issue:3 Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Drug Delivery Systems; Humans; Injections, Intra-Arterial; Lung Neoplasms; Male; Middle Aged; Neurotoxicity Syndromes; Rats; Rats, Nude; Small Cell Lung Carcinoma; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2016
Excessive neurotoxicity with ABVD when combined with protease inhibitor-based antiretroviral therapy in the treatment of AIDS-related Hodgkin lymphoma. Clinical lymphoma, myeloma & leukemia, 2010, Volume: 10, Issue:2 Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Doxorubicin; HIV Infections; Hodgkin Disease; Humans; Incidence; Lymphoma, AIDS-Related; Male; Neoplasms; Neurotoxicity Syndromes; Protease Inhibitors; Vinblastine	2010

Article

Year

Intra-arterial administration improves temozolomide delivery and efficacy in a model of intracerebral metastasis, but has unexpected brain toxicity.

Journal of neuro-oncology, 2016, Volume: 126, Issue:3

Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Drug Delivery Systems; Humans; Injections, Intra-Arterial; Lung Neoplasms; Male; Middle Aged; Neurotoxicity Syndromes; Rats; Rats, Nude; Small Cell Lung Carcinoma; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2016

Excessive neurotoxicity with ABVD when combined with protease inhibitor-based antiretroviral therapy in the treatment of AIDS-related Hodgkin lymphoma.

Clinical lymphoma, myeloma & leukemia, 2010, Volume: 10, Issue:2

Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Doxorubicin; HIV Infections; Hodgkin Disease; Humans; Incidence; Lymphoma, AIDS-Related; Male; Neoplasms; Neurotoxicity Syndromes; Protease Inhibitors; Vinblastine

2010